zinc finger protein 833, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ZNF833P profile across patient tissues and cancer cell-line models. ZNF833P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF833P is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, ZNF833P RNA expression shows 8,351 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight MESO, COAD, and LIHC as cancer lineages where ZNF833P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF833P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF833P survival associations across molecular data types. ZNF833P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF833P RNA expression–survival associations across cancer types. High ZNF833P expression shows unfavorable associations in MESO, DLBC, ACC, STAD and LUSC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF833P RNA expression.
This table summarizes ZNF833P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF833P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF833P shows higher tumor expression in COAD and BLCA. The COAD box plot shows higher ZNF833P RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .008).
This table shows molecular features associated with ZNF833P in patient tissues and cancer cell lines. In patient samples, ZNF833P shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF833P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
